Sign in to edit your profile (add interests, mentoring, photo, etc.)

    David Cheresh

    SchoolUniversity of California, San Diego
    Address9500 Gilman Drive #0695
    CA La Jolla 92093
    vCardDownload vCard

      Collapse Research 
      Collapse Research Activities and Funding
      Targeting a non-canonical RAS-driven pathway in pancreatic cancer
      NIH/NCI R01CA168692Jul 1, 2012 - Apr 30, 2017
      Role: Principal Investigator
      MicroRNA regulation of RasGAP's during angiogenesis
      NIH/NHLBI R01HL103956Jun 15, 2011 - May 31, 2016
      Role: Principal Investigator
      Identification of novel pancreatic cancer biomarkers
      NIH/NCI R21CA129660Sep 1, 2007 - Aug 31, 2009
      Role: Principal Investigator
      Endothelial Barrier Function Regulation by VEGF
      NIH/NHLBI R01HL078912Aug 1, 2005 - Jul 31, 2010
      Role: Principal Investigator
      Targeting Vessels in Tumors
      NIH P01CA104898May 16, 2005 - Aug 31, 2011
      Role: Co-Investigator
      Biological Response to the Extracellular Matrix
      NIH/NCI R13CA094245Apr 1, 2002 - Dec 31, 2002
      Role: Principal Investigator
      Regulation of cell invasion by apoptotic mechanisms
      NIH/NCI R01CA095262Mar 1, 2002 - May 31, 2012
      Role: Principal Investigator
      Angiogenesis and Mircrocirculation Conference
      NIH/NCI R13CA092869Jun 1, 2001 - May 31, 2002
      Role: Principal Investigator
      NIH/NHLBI R13HL065737Aug 1, 2000 - Jul 31, 2001
      Role: Principal Investigator
      Combinatorial Chemistry and Cancer Target
      NIH P01CA078045May 7, 1998 - Feb 28, 2010
      Role: Co-Investigator
      Integrin Signaling in Hemostasis and Blood Diseases
      NIH/NHLBI P01HL057900Apr 1, 1997 - Jan 31, 2014
      Role: Co-Investigator
      NIH/NHLBI R01HL054444Jun 1, 1995 - May 31, 1999
      Role: Principal Investigator
      CRAF-mediated vascular resistance to cancer therapies
      NIH/NCI R01CA050286Aug 1, 1989 - Feb 29, 2020
      Role: Principal Investigator
      VEGF and PDGF in angiogenesis and tumor progression
      NIH/NCI R37CA050286Aug 1, 1989 - Apr 30, 2014
      Role: Principal Investigator
      Integrin alpha v beta 3 promotes resistance to EGF receptor inhibitors
      NIH/NCI R01CA045726Apr 1, 1988 - Jan 31, 2018
      Role: Principal Investigator
      NIH/NCI F32CA007544Mar 1, 1985
      Role: Principal Investigator

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Seguin L, Camargo MF, Wettersten HI, Kato S, Desgrosellier JS, von Schalscha T, Elliott KC, Cosset E, Lesperance J, Weis SM, Cheresh D. Galectin-3, a druggable vulnerability for KRAS-addicted cancers. Cancer Discov. 2017 Sep 11. PMID: 28893801.
        View in: PubMed
      2. Wilson R, Espinosa-Diez C, Kanner N, Chatterjee N, Ruhl R, Hipfinger C, Advani SJ, Li J, Khan OF, Franovic A, Weis SM, Kumar S, Coussens LM, Anderson DG, Chen CC, Cheresh D, Anand S. MicroRNA regulation of endothelial TREX1 reprograms the tumour microenvironment. Nat Commun. 2016 Nov 25; 7:13597. PMID: 27886180.
        View in: PubMed
      3. Advani SJ, Camargo MF, Seguin L, Mielgo A, Anand S, Hicks AM, Aguilera J, Franovic A, Weis SM, Cheresh D. Kinase-independent role for CRAF-driving tumour radioresistance via CHK2. Nat Commun. 2015 Sep 03; 6:8154. PMID: 26333361; PMCID: PMC4559870.
      4. Franovic A, Elliott KC, Seguin L, Camargo MF, Weis SM, Cheresh D. Glioblastomas require integrin avß3/PAK4 signaling to escape senescence. Cancer Res. 2015 Nov 01; 75(21):4466-73. PMID: 26297735; PMCID: PMC4631634 [Available on 11/01/16].
      5. Acevedo LM, Lindquist JN, Walsh BM, Sia P, Cimadamore F, Chen C, Denzel M, Pernia CD, Ranscht B, Terskikh A, Snyder EY, Cheresh D. hESC Differentiation toward an Autonomic Neuronal Cell Fate Depends on Distinct Cues from the Co-Patterning Vasculature. Stem Cell Reports. 2015 Jun 09; 4(6):1075-88. PMID: 26004631; PMCID: PMC4471822.
      6. Seguin L, Desgrosellier JS, Weis SM, Cheresh D. Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance. Trends Cell Biol. 2015 Apr; 25(4):234-40. PMID: 25572304; PMCID: PMC4380531.
      7. Desgrosellier JS, Lesperance J, Seguin L, Gozo M, Kato S, Franovic A, Yebra M, Shattil SJ, Cheresh D. Integrin avß3 drives slug activation and stemness in the pregnant and neoplastic mammary gland. Dev Cell. 2014 Aug 11; 30(3):295-308. PMID: 25117682; PMCID: PMC4147869.
      8. Seguin L, Gozo M, Weis SM, Cheresh D. Targeting the Achilles' heel of drug-resistant cancer stem cells. Cell Cycle. 2014; 13(13):2017-8. PMID: 24906000; PMCID: PMC4111689.
      9. Seguin L, Weis SM, Cheresh D. Variety in the tumor microenvironment: integrin splicing regulates stemness. Cell Stem Cell. 2014 May 01; 14(5):557-8. PMID: 24792112.
        View in: PubMed
      10. Seguin L, Kato S, Franovic A, Camargo MF, Lesperance J, Elliott KC, Yebra M, Mielgo A, Lowy AM, Husain H, Cascone T, Diao L, Wang J, Wistuba II, Heymach JV, Lippman SM, Desgrosellier JS, Anand S, Weis SM, Cheresh D. An integrin ß3-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition. Nat Cell Biol. 2014 May; 16(5):457-68. PMID: 24747441; PMCID: PMC4105198.
      11. Jean C, Chen XL, Nam JO, Tancioni I, Uryu S, Lawson C, Ward KK, Walsh CT, Miller NL, Ghassemian M, Turowski P, Dejana E, Weis S, Cheresh D, Schlaepfer DD. Inhibition of endothelial FAK activity prevents tumor metastasis by enhancing barrier function. J Cell Biol. 2014 Jan 20; 204(2):247-63. PMID: 24446483; PMCID: PMC3897185.
      12. Cheresh D, Stupack DG. Tumor angiogenesis: putting a value on plastic GEMMs. Circ Res. 2014 Jan 03; 114(1):9-11. PMID: 24385501; PMCID: PMC4090242.
      13. Weis SM, Cheresh D. A wake-up call for hibernating tumour cells. Nat Cell Biol. 2013 Jul; 15(7):721-3. PMID: 23817234.
        View in: PubMed
      14. Garmy-Susini B, Avraamides CJ, Desgrosellier JS, Schmid MC, Foubert P, Ellies LG, Lowy AM, Blair SL, Vandenberg SR, Datnow B, Wang HY, Cheresh D, Varner J. PI3Ka activates integrin a4ß1 to establish a metastatic niche in lymph nodes. Proc Natl Acad Sci U S A. 2013 May 28; 110(22):9042-7. PMID: 23671068; PMCID: PMC3670313.
      15. Lim ST, Miller NL, Chen XL, Tancioni I, Walsh CT, Lawson C, Uryu S, Weis SM, Cheresh D, Schlaepfer DD. Nuclear-localized focal adhesion kinase regulates inflammatory VCAM-1 expression. J Cell Biol. 2012 Jun 25; 197(7):907-19. PMID: 22734001; PMCID: PMC3384409.
      16. Lau SK, Shields DJ, Murphy EA, Desgrosellier JS, Anand S, Huang M, Kato S, Lim ST, Weis SM, Stupack DG, Schlaepfer DD, Cheresh D. EGFR-mediated carcinoma cell metastasis mediated by integrin avß5 depends on activation of c-Src and cleavage of MUC1. PLoS One. 2012; 7(5):e36753. PMID: 22586492; PMCID: PMC3346745.
      17. Yu PT, Babicky M, Jaquish D, French R, Marayuma K, Mose E, Niessen S, Hoover H, Shields D, Cheresh D, Cravatt BF, Lowy AM. The RON-receptor regulates pancreatic cancer cell migration through phosphorylation-dependent breakdown of the hemidesmosome. Int J Cancer. 2012 Oct 15; 131(8):1744-54. PMID: 22275185; PMCID: PMC3424378.
      18. Chen XL, Nam JO, Jean C, Lawson C, Walsh CT, Goka E, Lim ST, Tomar A, Tancioni I, Uryu S, Guan JL, Acevedo LM, Weis SM, Cheresh D, Schlaepfer DD. VEGF-induced vascular permeability is mediated by FAK. Dev Cell. 2012 Jan 17; 22(1):146-57. PMID: 22264731; PMCID: PMC3266538.
      19. Scheppke L, Murphy EA, Zarpellon A, Hofmann JJ, Merkulova A, Shields DJ, Weis SM, Byzova TV, Ruggeri ZM, Iruela-Arispe ML, Cheresh D. Notch promotes vascular maturation by inducing integrin-mediated smooth muscle cell adhesion to the endothelial basement membrane. Blood. 2012 Mar 01; 119(9):2149-58. PMID: 22134168; PMCID: PMC3311249.
      20. Anand S, Cheresh D. Emerging Role of Micro-RNAs in the Regulation of Angiogenesis. Genes Cancer. 2011 Dec; 2(12):1134-8. PMID: 22866204; PMCID: PMC3411126.
      21. Mielgo A, Seguin L, Huang M, Camargo MF, Anand S, Franovic A, Weis SM, Advani SJ, Murphy EA, Cheresh D. A MEK-independent role for CRAF in mitosis and tumor progression. Nat Med. 2011 Nov 13; 17(12):1641-5. PMID: 22081024; PMCID: PMC3233644.
      22. Weis SM, Cheresh D. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med. 2011 Nov 07; 17(11):1359-70. PMID: 22064426.
        View in: PubMed
      23. Weis SM, Cheresh D. aV integrins in angiogenesis and cancer. Cold Spring Harb Perspect Med. 2011 Sep; 1(1):a006478. PMID: 22229119; PMCID: PMC3234453.
      24. Schmid MC, Avraamides CJ, Dippold HC, Franco I, Foubert P, Ellies LG, Acevedo LM, Manglicmot JR, Song X, Wrasidlo W, Blair SL, Ginsberg MH, Cheresh D, Hirsch E, Field SJ, Varner JA. Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3k?, a single convergent point promoting tumor inflammation and progression. Cancer Cell. 2011 Jun 14; 19(6):715-27. PMID: 21665146; PMCID: PMC3144144.
      25. Aspinall RJ, Weis SM, Barnes L, Lutu-Fuga K, Bylund DJ, Pockros PJ, Cheresh D. A Src family kinase inhibitor improves survival in experimental acute liver failure associated with elevated cerebral and circulating vascular endothelial growth factor levels. Liver Int. 2011 Sep; 31(8):1222-30. PMID: 21745297; PMCID: PMC3337519.
      26. Anand S, Cheresh D. MicroRNA-mediated regulation of the angiogenic switch. Curr Opin Hematol. 2011 May; 18(3):171-6. PMID: 21423013; PMCID: PMC3159578.
      27. Murphy EA, Majeti BK, Mukthavaram R, Acevedo LM, Barnes LA, Cheresh D. Targeted nanogels: a versatile platform for drug delivery to tumors. Mol Cancer Ther. 2011 Jun; 10(6):972-82. PMID: 21518727; PMCID: PMC3112300.
      28. Anand S, Majeti BK, Acevedo LM, Murphy EA, Mukthavaram R, Scheppke L, Huang M, Shields DJ, Lindquist JN, Lapinski PE, King PD, Weis SM, Cheresh D. MicroRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis. Nat Med. 2010 Aug; 16(8):909-14. PMID: 20676106; PMCID: PMC3094020.
      29. Garmy-Susini B, Avraamides CJ, Schmid MC, Foubert P, Ellies LG, Barnes L, Feral C, Papayannopoulou T, Lowy A, Blair SL, Cheresh D, Ginsberg M, Varner JA. Integrin alpha4beta1 signaling is required for lymphangiogenesis and tumor metastasis. Cancer Res. 2010 Apr 15; 70(8):3042-51. PMID: 20388801; PMCID: PMC2856096.
      30. Murphy EA, Shields DJ, Stoletov K, Dneprovskaia E, McElroy M, Greenberg JI, Lindquist J, Acevedo LM, Anand S, Majeti BK, Tsigelny I, Saldanha A, Walsh B, Hoffman RM, Bouvet M, Klemke RL, Vogt PK, Arnold L, Wrasidlo W, Cheresh D. Disruption of angiogenesis and tumor growth with an orally active drug that stabilizes the inactive state of PDGFRbeta/B-RAF. Proc Natl Acad Sci U S A. 2010 Mar 02; 107(9):4299-304. PMID: 20154271; PMCID: PMC2840076.
      31. Desgrosellier JS, Cheresh D. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010 Jan; 10(1):9-22. PMID: 20029421; PMCID: PMC4383089.
      32. Shields DJ, Niessen S, Murphy EA, Mielgo A, Desgrosellier JS, Lau SK, Barnes LA, Lesperance J, Bouvet M, Tarin D, Cravatt BF, Cheresh D. RBBP9: a tumor-associated serine hydrolase activity required for pancreatic neoplasia. Proc Natl Acad Sci U S A. 2010 Feb 02; 107(5):2189-94. PMID: 20080647; PMCID: PMC2836678.
      33. Greenberg JI, Cheresh D. VEGF as an inhibitor of tumor vessel maturation: implications for cancer therapy. Expert Opin Biol Ther. 2009 Nov; 9(11):1347-56. PMID: 19761418.
        View in: PubMed
      34. Desgrosellier JS, Barnes LA, Shields DJ, Huang M, Lau SK, Prévost N, Tarin D, Shattil SJ, Cheresh D. An integrin alpha(v)beta(3)-c-Src oncogenic unit promotes anchorage-independence and tumor progression. Nat Med. 2009 Oct; 15(10):1163-9. PMID: 19734908; PMCID: PMC2759406.
      35. Weis SM, Stupack DG, Cheresh D. Agonizing integrin antagonists? Cancer Cell. 2009 May 05; 15(5):359-61. PMID: 19411065.
        View in: PubMed
      36. Makale M, McElroy M, O'Brien P, Hoffman RM, Guo S, Bouvet M, Barnes L, Ingulli E, Cheresh D. Extended-working-distance multiphoton micromanipulation microscope for deep-penetration imaging in live mice and tissue. J Biomed Opt. 2009 Mar-Apr; 14(2):024032. PMID: 19405761; PMCID: PMC3098575.
      37. Ricono JM, Huang M, Barnes LA, Lau SK, Weis SM, Schlaepfer DD, Hanks SK, Cheresh D. Specific cross-talk between epidermal growth factor receptor and integrin alphavbeta5 promotes carcinoma cell invasion and metastasis. Cancer Res. 2009 Feb 15; 69(4):1383-91. PMID: 19208836; PMCID: PMC2741736.
      38. Acevedo LM, Cheresh D. Suppressing NFAT increases VEGF signaling in hemangiomas. Cancer Cell. 2008 Dec 09; 14(6):429-30. PMID: 19061833.
        View in: PubMed
      39. Greenberg JI, Shields DJ, Barillas SG, Acevedo LM, Murphy E, Huang J, Scheppke L, Stockmann C, Johnson RS, Angle N, Cheresh D. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature. 2008 Dec 11; 456(7223):809-13. PMID: 18997771; PMCID: PMC2605188.
      40. Stockmann C, Doedens A, Weidemann A, Zhang N, Takeda N, Greenberg JI, Cheresh D, Johnson RS. Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature. 2008 Dec 11; 456(7223):814-8. PMID: 18997773; PMCID: PMC3103772.
      41. Murphy EA, Majeti BK, Barnes LA, Makale M, Weis SM, Lutu-Fuga K, Wrasidlo W, Cheresh D. Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proc Natl Acad Sci U S A. 2008 Jul 08; 105(27):9343-8. PMID: 18607000; PMCID: PMC2453735.
      42. Scheppke L, Aguilar E, Gariano RF, Jacobson R, Hood J, Doukas J, Cao J, Noronha G, Yee S, Weis S, Martin MB, Soll R, Cheresh D, Friedlander M. Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits. J Clin Invest. 2008 Jun; 118(6):2337-46. PMID: 18483622; PMCID: PMC2381746.
      43. Serban D, Leng J, Cheresh D. H-ras regulates angiogenesis and vascular permeability by activation of distinct downstream effectors. Circ Res. 2008 Jun 06; 102(11):1350-8. PMID: 18467631; PMCID: PMC2743877.
      44. Weis SM, Lim ST, Lutu-Fuga KM, Barnes LA, Chen XL, Göthert JR, Shen TL, Guan JL, Schlaepfer DD, Cheresh D. Compensatory role for Pyk2 during angiogenesis in adult mice lacking endothelial cell FAK. J Cell Biol. 2008 Apr 07; 181(1):43-50. PMID: 18391070; PMCID: PMC2287283.
      45. Acevedo LM, Weis SM, Cheresh D. Robo4 counteracts VEGF signaling. Nat Med. 2008 Apr; 14(4):372-3. PMID: 18391935.
        View in: PubMed
      46. Acevedo LM, Barillas S, Weis SM, Göthert JR, Cheresh D. Semaphorin 3A suppresses VEGF-mediated angiogenesis yet acts as a vascular permeability factor. Blood. 2008 Mar 01; 111(5):2674-80. PMID: 18180379; PMCID: PMC2254547.
      47. Luo JL, Tan W, Ricono JM, Korchynskyi O, Zhang M, Gonias SL, Cheresh D, Karin M. Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature. 2007 Apr 05; 446(7136):690-4. PMID: 17377533.
        View in: PubMed
      48. Alavi AS, Acevedo L, Min W, Cheresh D. Chemoresistance of endothelial cells induced by basic fibroblast growth factor depends on Raf-1-mediated inhibition of the proapoptotic kinase, ASK1. Cancer Res. 2007 Mar 15; 67(6):2766-72. PMID: 17363598.
        View in: PubMed
      49. Doukas J, Wrasidlo W, Noronha G, Dneprovskaia E, Fine R, Weis S, Hood J, Demaria A, Soll R, Cheresh D. Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury. Proc Natl Acad Sci U S A. 2006 Dec 26; 103(52):19866-71. PMID: 17172449; PMCID: PMC1702529.
      50. Weis SM, Lindquist JN, Barnes LA, Lutu-Fuga KM, Cui J, Wood MR, Cheresh D. Cooperation between VEGF and beta3 integrin during cardiac vascular development. Blood. 2007 Mar 01; 109(5):1962-70. PMID: 17062734; PMCID: PMC1801042.
      51. Stupack DG, Teitz T, Potter MD, Mikolon D, Houghton PJ, Kidd VJ, Lahti JM, Cheresh D. Potentiation of neuroblastoma metastasis by loss of caspase-8. Nature. 2006 Jan 05; 439(7072):95-9. PMID: 16397500.
        View in: PubMed
      52. Weis SM, Cheresh D. Pathophysiological consequences of VEGF-induced vascular permeability. Nature. 2005 Sep 22; 437(7058):497-504. PMID: 16177780.
        View in: PubMed
      53. Potter MD, Barbero S, Cheresh D. Tyrosine phosphorylation of VE-cadherin prevents binding of p120- and beta-catenin and maintains the cellular mesenchymal state. J Biol Chem. 2005 Sep 09; 280(36):31906-12. PMID: 16027153.
        View in: PubMed
      54. Weis S, Cui J, Barnes L, Cheresh D. Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. J Cell Biol. 2004 Oct 25; 167(2):223-9. PMID: 15504909; PMCID: PMC2172541.
      55. Weis S, Shintani S, Weber A, Kirchmair R, Wood M, Cravens A, McSharry H, Iwakura A, Yoon YS, Himes N, Burstein D, Doukas J, Soll R, Losordo D, Cheresh D. Src blockade stabilizes a Flk/cadherin complex, reducing edema and tissue injury following myocardial infarction. J Clin Invest. 2004 Mar; 113(6):885-94. PMID: 15067321; PMCID: PMC362122.
      56. Wakasugi K, Slike BM, Hood J, Ewalt KL, Cheresh D, Schimmel P. Induction of angiogenesis by a fragment of human tyrosyl-tRNA synthetase. J Biol Chem. 2002 Jun 07; 277(23):20124-6. PMID: 11956181.
        View in: PubMed